[{"data":1,"prerenderedAt":140},["ShallowReactive",2],{"drug-lidocaine-patch":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":34,"contraindications":54,"warnings":64,"renal":72,"monitoring":73,"interactions":74,"review":75,"examples":78,"atc":79,"iran":81,"links":88,"populations":108,"usApproval":135},"lidocaine-patch",1,{"fa":7,"en":8},"چسب لیدوکائین ۵٪","Lidocaine patch 5%","nervous-system",{"fa":11,"en":12},"بی‌حس‌کننده موضعی","Local anaesthetic",[14],{"name":15,"market":16},"Lidoderm","US",[18,19,20],"lidoderm","versatis","چسب لیدوکائین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":29,"refs":30},"patch-5","cream","topical","Lidocaine 5% patch (700 mg)",{"amount":5,"unit":28,"perUnit":28},"application",[16],[31],{"source":32,"section":33},"fda-lidoderm","How Supplied",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":46,"dose":47,"refs":51},"phn","postherpetic-neuralgia",{"fa":39,"en":40},"نورالژی پس از زونا — تا ۳ چسب حداکثر ۱۲ ساعت در ۲۴ ساعت","Postherpetic neuralgia — up to 3 patches for max 12 h in 24 h",{"minAge":42},{"value":43,"unit":44},18,"year","notCalculated","mg",{"reason":48},{"fa":49,"en":50},"روی پوست سالم و دردناک‌ترین ناحیه؛ حداکثر ۳ چسب، فقط یک بار تا ۱۲ ساعت در هر ۲۴ ساعت. می‌توان چسب را برید. در بیمار ناتوان یا با دفع مختل، ناحیه کوچک‌تر.","On intact skin over the most painful area; max 3 patches, once for up to 12 h in any 24 h. Patches may be cut. Smaller areas in debilitated patients or impaired elimination.",[52],{"source":32,"section":53},"Dosage and Administration",[55],{"id":56,"severity":57,"text":58,"refs":61},"amide","block",{"fa":59,"en":60},"سابقه حساسیت به بی‌حس‌کننده‌های آمیدی یا اجزای چسب.","History of sensitivity to amide local anaesthetics or any component.",[62],{"source":32,"section":63},"Contraindications",[65],{"text":66,"refs":69},{"fa":67,"en":68},"خطر مت‌هموگلوبینمی (به‌ویژه در کمبود G6PD و شیرخوار زیر ۶ ماه).","Risk of methaemoglobinaemia (especially with G6PD deficiency and infants under 6 months).",[70],{"source":32,"section":71},"Warnings",[],[],[],{"status":76,"reviewer":77,"date":77},"unverified",null,[],[80],"N01BB02",{"status":82,"refs":83},"not-found",[84],{"source":85,"section":86,"url":87},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Lidocaine%20patch",[89,93,97,101,104],{"kind":90,"url":91,"label":92},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020612","NDA020612",{"kind":94,"url":95,"label":96},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=db0092f5-02a0-4076-ac32-969f075a6ab1","FDA Lidoderm",{"kind":98,"url":99,"label":100},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa603026.html","Lidocaine Transdermal Patch",{"kind":102,"url":103,"label":80},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N01BB02",{"kind":105,"url":106,"label":107},"darooyab","https:\u002F\u002Fwww.darooyab.ir\u002FG-2764\u002FLidocaine-Local","Lidocaine-Local",{"pregnancy":109,"lactation":118,"pediatric":126},{"level":110,"text":111,"quote":114,"refs":115},"caution",{"fa":112,"en":113},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Teratogenic Effects Pregnancy Category B.",[116],{"source":32,"section":117},"Pregnancy",{"level":110,"text":119,"quote":122,"refs":123},{"fa":120,"en":121},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Caution should be exercised when LIDODERM is administered to a nursing woman.",[124],{"source":32,"section":125},"Nursing Mothers",{"level":127,"text":128,"quote":131,"refs":132},"not-established",{"fa":129,"en":130},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[133],{"source":32,"section":134},"Pediatric Use",{"kind":136,"refs":137,"id":92},"NDA",[138],{"source":32,"section":139},"SPL approval \u002F marketing category",1792111459114]